Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

BACKGROUND: Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results. We report updated ZUMA-3 outcomes with longer foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Bijal D., Ghobadi, Armin, Oluwole, Olalekan O., Logan, Aaron C., Boissel, Nicolas, Cassaday, Ryan D., Leguay, Thibaut, Bishop, Michael R., Topp, Max S., Tzachanis, Dimitrios, O’Dwyer, Kristen M., Arellano, Martha L., Lin, Yi, Baer, Maria R., Schiller, Gary J., Park, Jae H., Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C., Wierda, William G., DeAngelo, Daniel J., Stiff, Patrick, Jeyakumar, Deepa, Dong, Jinghui, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C., Faghmous, Imi, Masouleh, Behzad Kharabi, Houot, Roch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734710/
https://www.ncbi.nlm.nih.gov/pubmed/36494725
http://dx.doi.org/10.1186/s13045-022-01379-0

Ejemplares similares

Ejemplares similares